What is the recommended management plan for plaque psoriasis?

Management of Plaque Psoriasis

For mild to moderate plaque psoriasis, start with topical vitamin D analogues (calcipotriene) combined with high-potency topical corticosteroids for up to 52 weeks; for moderate to severe disease, initiate biologics targeting IL-17 (ixekizumab, bimekizumab) or IL-23 (risankizumab) as first-line systemic therapy, as these demonstrate superior efficacy to traditional agents like methotrexate. 1, 2

Mild to Moderate Psoriasis: Topical Therapy Algorithm

First-Line Topical Treatment

• Combination therapy is superior to monotherapy: Use calcipotriene/betamethasone dipropionate combination products as initial treatment (Strength A recommendation) 1
• Duration: Safe and effective for up to 52 weeks of continuous use 1
• Application regimen options:
  • Fixed combination product daily, OR
  • Vitamin D analogue twice daily on weekdays + high-potency corticosteroid twice daily on weekends for maintenance (Strength B) 1
  • Morning high-potency corticosteroid + evening vitamin D analogue (Strength B) 1

Site-Specific Considerations

• Scalp psoriasis: Calcipotriene foam or calcipotriene/betamethasone gel for 4-12 weeks (Strength A) 1
• Facial psoriasis: Tacalcitol ointment or calcipotriene combined with hydrocortisone for 8 weeks (Strength B) 1
• Nail psoriasis: Tazarotene 0.1% cream under occlusion or calcipotriene/betamethasone (limited efficacy due to poor penetration) 1

Important Caveat

Avoid simultaneous use of salicylic acid with calcipotriene - the acidic pH inactivates calcipotriene and reduces effectiveness 1

Alternative Topical Options

• Tazarotene 0.1% cream or gel: Recommended for 8-12 weeks, comparable efficacy to fluocinonide cream 1
• Tapinarof cream: Novel non-steroidal AHR agonist, FDA-approved for adults, provides long duration of effect even after discontinuation 3

Moderate to Severe Psoriasis: Systemic Therapy Algorithm

First-Line Systemic Options

The most effective biologics based on network meta-analysis are 2:

1. Infliximab
2. Bimekizumab (IL-17 inhibitor)
3. Ixekizumab (IL-17 inhibitor)
4. Risankizumab (IL-23 p19 inhibitor)

These four agents showed statistically similar clinical effectiveness when compared head-to-head, with no significant differences in serious adverse events versus placebo 2.

Biologic Selection Strategy

IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab):

• Highest efficacy for cutaneous clearance
• Also effective for psoriatic arthritis (peripheral, not axial) 4

IL-23 p19 inhibitors (guselkumab, tildrakizumab, risankizumab):

• Excellent long-term durability
• Less frequent dosing intervals
• Also effective for psoriatic arthritis 4

TNF-α inhibitors (etanercept, adalimumab, infliximab, certolizumab):

• Effective for both skin and psoriatic arthritis
• More extensive long-term safety data
• Methotrexate is less effective than adalimumab and infliximab (Strength A) 5

IL-12/23 p40 inhibitor (ustekinumab):

• Moderate efficacy, good safety profile
• Convenient dosing (every 12 weeks after loading) 4

Traditional Systemic Agents

Methotrexate (Strength A recommendation for moderate-to-severe psoriasis) 5:

• Dosage: 7.5-25 mg weekly (oral or subcutaneous)
• Always co-administer folic acid or folinic acid to reduce GI and hepatic adverse effects (Strength A), but avoid large doses that may reduce efficacy 5
• Monitoring: Liver function tests every 3-6 months; baseline and annual hepatic serology for high-risk patients 5
• Contraindicated: Cirrhosis, significant cytopenias, pregnancy, nursing 5
• Wait 3 months after discontinuation before attempting pregnancy 5
• Less effective than biologics but acceptable first-line option per French guidelines 6

Combination Strategies for Enhanced Efficacy

Topicals + Biologics:

• Class 1 ultrahigh-potency corticosteroid + etanercept for 12 weeks (Strength A) 1
• Calcipotriene/betamethasone + adalimumab for 16 weeks accelerates plaque clearance (Strength B) 1
• All topical corticosteroids can be combined with any biologic (Strength C) 1

Topicals + Methotrexate:

• Adding topical calcipotriene to methotrexate is recommended for moderate-to-severe disease (Strength A) 1

Methotrexate + Phototherapy:

• Combination with narrowband UVB enhances efficacy and lowers cumulative doses of both treatments (Strength B) 5

Treatment Target and Monitoring

The treat-to-target approach should be multidimensional 7:

• Objective severity measures (PASI, BSA)
• Clinician-reported outcomes
• Patient-reported outcomes (quality of life, symptom burden)

Recognize when treatment modification is warranted: If targets are not met within expected timeframes (typically 12-16 weeks for biologics), optimize or switch therapy rather than continuing inadequate treatment 7.

Special Populations

Psoriatic arthritis: Prioritize TNF inhibitors, IL-17 inhibitors, or IL-23 inhibitors over methotrexate, as methotrexate has lower efficacy than TNF inhibitors for psoriatic arthritis (Strength B) and is ineffective for axial involvement 5

Comorbidities: Address cardiovascular disease risk, obesity, and depression as integral components of psoriasis management - these comorbidities increase mortality and worsen outcomes if neglected 8